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1. Introduction
In the last century, the definition of COPD was considered as a disease constituted by chron‐
ic bronchitis and pulmonary emphysema; however, nowadays these terms are in disuse. In
the last decades emerged the Global Initiative for Chronic Obstructive Lung Disease
(GOLD), a group formed by researches with the objective of count with a diagnostic guide
to study this disease. According to the GOLD, the COPD is a common preventable and
treatable disease, characterized by persistent airflow limitation that is usually progressive
and associated with an enhanced chronic inflammatory response in the airways and the
lung to noxious particles or gases, exacerbations and co-morbidities contribute to the overall
severity in individual patients [1]. However, some of the parameters and the definition have
been questioned [2-4].
The prevalence of COPD in developed countries ranges from 3 to 6% in subjects over 50
years of age. According to the National Center for Health Statistics (NCHS) in the United
States, prevalence of COPD was stable from 1998 through 2009 and was significantly higher
among women than in men, and the prevalence was higher in old groups. The prevalence
was high among non-Hispanic white (5.7%) and Puerto Rican (6.9%) adults, Mexican-Amer‐
ican adults had the lowest COPD prevalence (2.6%) [5]. The prevalence of COPD appears to
be increasing not only in many developed countries, but also in Latin America. COPD occu‐
pies the fourth place in terms of mortality around the world, in Mexico is currently located
between the sixth and the fourth. In 2005 there was more than 11 000 deaths in men, against
just over 9 000 in women, recent studies show that the prevalence is equal between men and
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women [6]. According the European Federation of Allergies and Airways Diseases (EFA), in
Europe the prevalence of COPD varies among the different countries, having in the ex‐
tremes more than 10% Germany and 2% in Netherlands: with an annual mortality of 0.28
per 1000 in Germany and 0.30 per 1000 in Austria [7]. An important problem is that COPD
prevalence varies across the world, mainly to the different definitions of the disease, leading
to an over-diagnosis or under-diagnosis.
Smoking contributes too many health problems including cancer, cardiovascular disease,
and lung diseases, among others. In respiratory illnesses smoking increase the probability of
bronchitis, emphysema, chronic obstructive lung disease and pneumonia [8]. Diagnoses of
these illnesses are more common in smokers than in non-smokers; in fact is the most impor‐
tant risk factor of COPD and their health complications [1,9]. Therefore, in a person with the
diagnosis COPD, if it is smoking, the intervention plan should include the elimination of the
tobacco, since it is the most effective measurement in the prevention of this illness, provok‐
ing a delay in the loss of the pulmonary function and improving the survival [10].
2. Pathophysiology
The exposure to noxious particles produces lung inflammation, this chronic inflammation
produces several airways disease as obstructive bronchiolitis and parenchymal destruction
(known as emphysema) and impair defense mechanisms, all these changes result in a pro‐
gressive airflow limitation [1].
The main risk factors for COPD are tobacco smoking, occupational dusts and chemicals, in‐
door and outdoor air pollution. In countries as Mexico, Nepal, New Guinea and Colombia,
exposure to wood smoke also cause COPD. Inhalation in the work environment of dusts,
gases, fumes and chemicals are other risk factors. For example in United States 19% of pa‐
tients with COPD had an occupational exposure.
The symptoms more frequently observed include dyspnea, chronic cough and excessive
sputum production or expectoration. However, COPD is not just simply a "smoker's cough",
but an under-diagnosed, life threatening lung disease that may progressively lead to death.
Physical examination includes cyanosis of lips and fingers, breathing with pursed lips (more
common in patients with emphysema), use of accessory muscles of respiration: scalene and
sternocleidomastoid (in cases of severe COPD), engorgement jugular, decrease in respirato‐
ry or abolished (in severe stages of COPD) noise, vibrations reduced vowels (advanced
stage), there may be wheezing.
The spirometry is a simple diagnostic test that confirms the presence of COPD, it measures
the amount and speed of air inhaled and exhaled. Spirometry measures the forced expirato‐
ry volume in one second (FEV1), which is the greatest volume of air that can be breathed out
in the first second of a large breath; also measures the forced vital capacity (FVC), which is
the greatest volume of air that can be breathed out in a completely large breath (OMS). Nor‐
mally, at least 70% of the FVC comes out in the first second (i.e. the FEV1/FVC ratio is
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>70%). A ratio less than normal defines the patient as having COPD. The diagnosis of COPD
is made when the FEV1/FVC ratio is <70%. The GOLD criteria also require that values be
after bronchodilator medication has been given to make the diagnosis, and the NICE criteria
require FEV1%. According to the ERS criteria, it is FEV1% predicted that defines when a pa‐
tient has COPD, that is, when FEV1% predicted is < 88% for men, or < 89% for women [1].
At  the  beginning,  the  airflow  obstruction  first  causes  breathlessness  that  reduces  the
forced expiratory volume in one second (FEV1) to about 1 liter, which is less than half the
normal  value.  Then,  the condition progresses  persistently  over  five or  more years,  with
further loss of FEV, causing more and more distressing disability and, finally, death from
respiratory  failure  [11].  The  (FEV1)  declines  normally  with  aging  by  approximately  30
mL/yr, but in vulnerable smokers, the decline is greater (about 60 mL/yr), resulting in the
development  of  COPD.  Smoking  cessation  usually  restores  the  normal  or  near-normal
rate of FEV1 decline. Therefore, smoking cessation is a critical component for the preven‐
tion of COPD progression. FEV1 is an index in the definition of COPD and classification
of its severity. FEV1 is a good predictor of exercise tolerance and correlates with survival
and quality  of  life.  More  rapid  FEV1 decline  is  also  predictive  of  morbidity,  mortality,
and hospitalization rates [12].
3. Smoking cessation
With regard to lung diseases, COPD is which is more associated with cigarette smoking.
Smoking cessation reduces the risk of COPD, improves the prognosis [11,13], prevents pro‐
gression of the disease [14], and reduces exacerbations of COPD [15-17]. However, COPD
patients find it difficult to quit smoking; in fact, the majority of new patients to the hospital
for exacerbation of COPD continue smoking. COPD patients have a long smoking history,
higher tobacco consumption, higher level of CO in the exhaled air, severe dependence to
nicotine, and most have experienced numerous unsuccessful previous quit attempts [18,19].
This makes smoking cessation even more difficult for this group. Smoke quitting not only
reduces the risk of COPD but also improve some symptoms like cough, coughing, shortness
of breath and immune response, which leads to fewer respiratory infections to occur [20].
There are different drug treatments to quit smoking, however, when pharmacological treat‐
ments are combined with psychological techniques, the effectiveness increased significantly
in patients with COPD [20-22]. Coronini-Cronberg et al. [21] pointed out that the main prob‐
lems associated with the relapse of smoking in patients with COPD are the lack of motiva‐
tion to quit smoking, poor communication with healthcare professionals, and the misleading
information of the effects of smoking on health.
In patients with COPD, the comorbidity with anxiety and depression becomes more rele‐
vant. For that reason, it is important to review the available literature related to psychologi‐
cal techniques to quit smoking, specifically focused on psychological techniques to increase
motivation, development of skills to deal with situations to prevent relapse, and the man‐
agement of anxiety, depression, and stress. Therefore, the objective of this study was to con‐
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duct a review of the effectiveness of the treatments to quit smoking in patients with COPD,
identifying the main difficulties to maintain abstinence and propose strategies to eliminate
such obstacles.
4. Method
To perform this bibliographic review it was searched in the Cochrane Tobacco Addiction
Group, as well as the databases MEDLINE, EMBASE, PsycINFO, PubMed, and SCOPUS
from 2000 to 2012. We used the following keywords: smoking cessation, tobacco cessation,
hospital, patient, medical setting, and chronic obstructive pulmonary disease. The inclusion
criteria used in this review were: a) studies involving interventions for smoking cessation in
smokers who have COPD, b) that smokers had 18 or more years; and c) that smokers submit
voluntarily to interventions for smoking cessation.
5. Results
Ten reports were identified and grouped in three categories:
a. Studies with an experimental group with a psychological intervention (2)
b. Studies with an experimental group in which the treatment consisted of the combina‐
tion of any pharmacological treatment with psychological intervention to quit smoking
(6), and
c. Studies in which the intervention was done in hospitalized patients (2).
6. Psychological interventions for smoking cessation in patients with
COPD
In a review on the effectiveness of interventions for smoking cessation, Lancaster and Stead
[23] point out that psychological interventions that use behavioral and cognitive behavioral
techniques are effective (e.g. control of stimuli, self-management, coping skills). In the same
way, van der Meer et al. [24] reviewed the effectiveness of interventions for smoking cessa‐
tion in people with COPD. The five studies included show the effectiveness of psychosocial
interventions combined with pharmacological intervention: psychosocial interventions com‐
bined with NRT and a bronchodilator respect to any treatment with a 5-year follow-up (RD
= 0.16, RR = 4, 0); psychosocial interventions combined with NRT and placebo with respect
to any treatment with a 5-year follow-up (RD = 0.17, RR = 4.19). In addition the results dem‐
onstrated the effectiveness of various combinations of psychosocial and pharmacological in‐
terventions in the follow up at 6 months (RD = 0.07, RR = 1.74). The limitation of this review
is that none of the included studies compared psychosocial interventions without pharma‐
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cotherapy. It is concluded that a combination of psychosocial and pharmacological interven‐
tions are superior to none apply any treatment. However, few studies have evaluated in the
context of clinical trials the effectiveness of psychological interventions in patients with
COPD (see table 1).
Hilberink, Jacobs, Bottema of Vries, and Grol [25] conducted in the Netherlands a random‐
ized controlled trial in patients with COPD (392 smokers) to evaluate the type of interven‐
tion on smoking cessation rates, the interventions were a minimal intensity intervention for
smoking cessation or the usual care. The intervention was educational and included patient
support by health professionals. In the first visit, it was spoken of symptoms, health status
and treatment, smoking behavior and motivational state for smoking cessation; also a bro‐
chure and a video designed for people with COPD were given. Based on the stages of
change [26], the patients were assigned in three categories: 1) preparers (wanted to quit in
the next month), 2) contemplators (wanted to quit in the next 6 months), and 3) precontem‐
plators (not want to quit). According to these categories, smokers with no motivation to
quit, just received information about the benefits of quitting (control group). Smokers moti‐
vated to quit received information to increase their self-efficacy from discussing how they
could deal with barriers to quitting, and additionally, information on nicotine replacement
therapies according to the level of nicotine dependence was given. After six months, the ex‐
perimental group showed more attempts to quit smoking (44.9% vs. 36.5%), and quit smok‐
ing compared with control group (16.0% vs. 8.8%).
In a second study Wilson, Fitzsimons, Bradbury and Stuart [27] conducted a randomized
controlled trial to evaluate the effectiveness of interventions to quit smoking based on the
brief  advise  or  brief  advise  accompanied  by  nurse  support,  either  individually  or  in
group; smoking status was biochemically validated at 2, 3, 6, 9 and 12 months. The sam‐
ple consisted of 91 smokers with COPD from an Ireland hospital. All patients received a
brief smoking cessation intervention from the physician (5-10 minutes); afterwards, smok‐
ers were randomly assigned to one of three groups: usual care, individual, or group sup‐
port.  The usual care group (n = 35) or control group, received only the brief advise; the
intervention groups,  individual  support  (n  =  27)  or  group support  (n  =  29),  underwent
five  weeks  of  support  after  the  intervention;  the  nurses  with  approximately  6  hours  of
training carried out the interventions. Individual interventions consisted in providing self-
help  material  and  information  about  the  personal  benefits  of  quit  smoking,  discussion
about  the  benefits  of  nicotine  replacement  therapy,  to  encourage  setting  a  date  to  stop
smoking and inform friends and family about the intent. In group interventions, patients
were classified according to the phase of change [26] in order that nurses could adapt the
intervention to the phase of each patient. In addition, the positive and negative aspects of
smoking,  particularly  on  health  were  discussed,  as  well  as  the  previous  efforts  to  quit
smoking with the intention of to identify those factors that contributed to relapse. In addi‐
tion,  role  play  in  risk  situations  was  performed to  increase  their  confidence  to  quitting
smoking. Both interventions consisted of five sessions of 60 minutes, in which nicotine re‐
placement therapy was given upon request. Twelve months after the intervention, no sig‐
nificant differences between the groups were observed. Abstinence in patients was of 6%
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in control group and of 10% in intervention group, a significant reduction of their addic‐
tion to nicotine was observed in all  groups.  These data lead to the authors to conclude
that patients with COPD were unable to quit smoking, regardless of the type of support
they receive. Therefore, the reduction of tobacco consumption may be an alternative goal
for these smokers.
7. Combination of pharmacological and psychological interventions for
smoking cessation in patients with COPD
Pharmacologic therapies have as main function the relief of withdrawal symptoms pro‐
duced by suppressing the consumption of tobacco and consequently help people quit smok‐
ing. Pharmacological therapies are classified in two categories, the nicotinic therapies such
as nicotine gum, nicotine transdermal patch and inhaler, and non-nicotinic therapies such as
bupropion, nortriptyline and varenicline [28]. A review of clinical trials to assess the effec‐
tiveness of nicotinic therapies to smokers without chronic disease, describes that all these
types of treatments increase the probability of abstinence and is higher than placebo [29].
While with non-nicotinic drug therapy in smokers without the diagnosis of a chronic dis‐
ease, varenicline and bupropion are most effective because the rate abstinence is higher than
placebo or with any other treatment to stop smoking.
Several clinical trials had evaluated whether the efficacy of drug therapy increases when
is combined with psychological intervention in patients with chronic diseases. For exam‐
ple, Molyneux et al. [30] compared NRT with placebo NRT or with no NRT. All subjects
received  a  counseling  intervention  for  smoking  cessation.  They  found  that  counseling
without NRT was equally effective. Another trial compared the effect of incorporating in‐
tensive  cognitive-behavioral  intervention  or  minimal  counseling  intervention  combined
with NRT [31]. The results showed that smoking cessation did not improve long-term quit
rates with NRT interventions. The results are conflicting, some studies show that there is
no increase in efficiency and others mention that it is indispensable the inclusion of a psy‐
chological intervention [24]. In the present review, we identified six studies (table 1) com‐
bining  a  psychological  intervention  with  pharmacological  therapy  (bupropion,
nortriptyline, varenicline or nicotine sublingual tablet).
In the first report [32] examined the effect of nicotine replacement therapy (NRT) in pa‐
tients  with  COPD.  In  a  double-blind,  multicenter,  placebo-controlled trial  involving 370
patients the efficacy of sublingual tablets or placebo combined with two levels of behavio‐
ral  support  for  smoking cessation in COPD patients  who smoked on average 19.6  ciga‐
rettes per day was evaluated, 6 and 12 months after treatment.
Participants were assigned to one of four experimental conditions: 1) nicotine sublingual
tablet with low behavioral support, 2) nicotine sublingual tablet with high behavioral sup‐
port, 3) placebo sublingual tablet with low behavioral support or 4) placebo sublingual tab‐
let with high behavioral support. The instructions given by nurses were to use nicotine
tablets according to the number of cigarettes smoked per day. One or 2 tablets per hour
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(minimum 10 tablets and maximum 40 tablets per day) for over 16 cigarettes; 1 tablet per
hour (6 to 30 tablets per day) for 10 to 15 cigarettes and 1 tablet per hour (3 to 10 tablets per
day) those who smoked 6 to 9 cigarettes. Abstinence rates were statistically significantly su‐
perior with nicotine sublingual tablets (low support 14% vs. high support 14%) compared to
placebo (low support 5% vs. high support 6%).
No statistical differences were found between the different intensity of behavioral support.
The main findings were sustained abstinence rates with nicotine sublingual tablet compared
with placebo in a group of patients with mild, moderate and severe COPD. The authors
point out the efficacy of NRT in combination with a smoking cessation program and suggest
that NRT should be used for smoking cessation in smokers with COPD, regardless of the
severity of the disease and the number of cigarettes smoked.
In the second report [33] the objective was to identify the factors detected in the initial as‐
sessment to predict abstinence in COPD patients when two different interventions were ap‐
plied. The patients (N=225) with moderate to severe COPD were assigned to one of two
interventions: 1) Minimal Intervention Strategy for Lung Patients (LMIS) of 180 min which
consisted of individual counseling and telephone contacts and the use of pharmacological
treatment was recommended if patients required or 2) Intensive Intervention [Smoke Stop
Therapy (SST)] with 595 min of duration which consisted of group and individual counsel‐
ing, telephone calls and support for the use of bupropion (available for the patients). In a
one-year follow-up, the continuous abstinence rates (validated with cotinine in saliva) were
9% for LMIS and 19% for SST [RR = 2.22, 95% CI: 1.06-4.65]. Regarding variables identifica‐
tion to predict abstinence, the SST was no predictor for success; while for LMIS the attitude
toward smoking cessation (OR: 11.8, 95% CI: 1.7-8.15, p =.013) and cotinine level (OR: 2.1,
95% CI: 1.08-3.93, p =.028) were significant predictors, 31% the variance in continuous absti‐
nence was explained by these variables (p =.003). It is concluded that LMIS is suitable for
COPD patients with a positive attitude to smoking cessation. SST may be an alternative for
patients without such features.
Tashkin et al. [19] conducted a study to investigate the effect of bupropion in promoting ab‐
stinence from smoking in patients with COPD. Smokers (N=404) with mild or moderate
COPD, who smoked 15 or more cigarettes per day, were assigned randomly to two groups
receiving one of two treatments for 12 weeks: intervention group with bupropion (150 mg,
twice daily) or placebo control. All patients received smoking cessation counseling by a
nurse or doctor; each patient received telephone counseling to quit smoking for 3 days after
discharge of the hospital and followed personally in each visit to the hospital. Medication
was taking one week before patients attempted to quit. The objective was to obtain complete
and continuous abstinence from week 4 until the end of week 7; there was a follow-up at 6
months. The abstinence rates were significantly higher in participants with bupropion com‐
pared with placebo (28% vs. 16%, p = 0.003). The abstinence rate between weeks 4 to 12 (18%
vs. 10%) and between weeks 4 to 26 (16% vs. 9%) also were higher in participants receiving
bupropion (p <0.05). The authors concluded that bupropion along with the counselling was
an effective aid to smoke cessation in patients with COPD.
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Wagena, Knipschild, Huibers, Wouters and van Schayck [34] explored the efficacy of bu‐
propion and nortriptyline in smokers at risk of COPD versus smokers with COPD. In a
randomized placebo-controlled,  double  blind trial,  255  adults  at  risk  for  COPD or  with
COPD were assigned to one of three groups that received different smoking cessation in‐
tervention:  a)  bupropion (15 mg twice daily),  b)  nortriptyline (75 mg once daily)  for  12
weeks and c) placebo bupropion. All patients received advice to quit smoking. The main
indicator of  outcome was prolonged abstinence from smoking from 4 to 26 weeks after
beginning the date  of  withdrawal.  The results  showed that  bupropion (27.9%) and nor‐
triptyline (25%) had high rates of prolonged abstinence at 26 weeks follow-up compared
with placebo (14.6%), significant differences between bupropion and placebo were detect‐
ed (p = 0.03),  13.1% [95% CI: -1.2% to 25.1%], and no differences for nortriptyline 10.2%
[95%  CI:  1.7%  to  22.2%).  In  patients  with  COPD,  bupropion  (27.3%)  and  nortriptyline
(21.2%)  were  equally  effective  in  prolonged  abstinence  rates  (differences  with  placebo
18.9% [95% CI: 3.6% -34.2%], for bupropion and 12.9% [95% CI: -0.8% to 26.4%] for nor‐
triptyline). In subjects with COPD risk, no statistically significant differences were detect‐
ed  compared  with  placebo  in  prolonged  abstinence  rates  (bupropion=  28.6%  vs.
nortriptyline= 32.1% vs. placebo = 22%). The authors conclude that bupropion combined
with smoking cessation counselling is an effective treatment for smoking cessation in pa‐
tients with COPD and nortriptyline is a useful alternative.
van Schayck, et al. [35] conducted a randomized, double-blind placebo-controlled trial to
evaluate the efficacy of bupropion and nortriptyline in combination with behavioral cogni‐
tive intervention in smokers with COPD risk in Netherlands. Smokers (n=255) with COPD
risk between 30-70 years, were counseled to quit smoking (three sessions of 20 minutes and
6 calls of 5 minutes). They were randomly allocated to one of three groups: bupropion, nor‐
triptyline or placebo for 12 weeks. The results showed prolonged abstinence rate (defined by
report of participants have not smoked in week 2 to 52 after the beginning of abstinence) for
bupropion (20.9%), nortriptyline (20%) and placebo (13.5%). Significant differences were ob‐
tained between bupropion and placebo [relative risk (RR) = 1.6, 95%, confidence interval
(CI) 0.8-3.0], in contrast, the differences between nortriptyline and placebo were not signifi‐
cant. The severity of the airway obstruction did not influence the significance of abstinence.
The social costs were € 1368 with bupropion, € 1906 with nortriptyline and € 1212 with pla‐
cebo. The authors concluded that bupropion and nortriptyline are equally effective, but bu‐
propion was more cost effective compared with placebo and nortriptyline. One possible
reason for the high cost of nortriptyline may be that participants who used nortriptyline ex‐
perienced more side effects from treatment.
Finally, one study evaluated varenicline combined with psychological intervention. In 27 cen‐
ters a randomized, controlled, double blind, trial in patients (N=504) with mild to moderate
COPD the efficacy of varenicline was evaluated [36]. The intervention consisted in 12 weeks of
varenicline with 40 weeks follow-up. All participants received an educational booklet on
smoking cessation information and brief counseling sessions (10 minutes) at each telephone
call or visit at the clinic. The primary endpoint to confirm the continuous abstinence rate with
the carbon monoxide level was week 9 to 12. The secondary endpoint was week 9 to 52. The re‐
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sults showed that the rate of continuous abstinence from week 9-12 was significantly higher for
patients in the varenicline group (42.3%) than for placebo patients (8.8%) (OR: 8.40, 95% CI: 4.99
-14.14, p <.0001). The continuous abstinence rate in patients treated with varenicline remained
significantly higher than for those treated with placebo through week 9 to 52 (18.6% vs. 5.6%)
(OR: 4.04, 95% CI: 2.13-7.67; p <.0001). Side effects commonly reported by patients in the vareni‐
cline group were nausea, nightmares, respiratory infection, and insomnia. The authors con‐
clude that varenicline was more effective than placebo for smoking cessation in patients with
mild and moderate COPD, and showed consistent with that observed in previous trials.
8. Interventions for smoking cessation in hospitalized patients with
COPD
An additional component in treatments for smoking cessation in patients with COPD is hospi‐
talization, which provides an excellent opportunity to help to stop smoking. Given that in this
condition the perceived vulnerability of patients increase, as well the receptivity to the messages
for the abandonment of smoking. In addition, access to health care allows patients to have direct
contact with health professionals who can provide messages or interventions for smoking cessa‐
tion, and smokers may find it easier to quit smoking in an environment smoke-free [37]. Despite
this, in practice few hospitals provide this kind of help to their patients. Table 1 shows interven‐
tion for smoking cessation in patients hospitalized for COPD.
Regarding the above, a study [38] measured in successive discharged patients of the de‐
partment of  neumology of  a  university hospital,  the percentage of  smoking history and
smoking cessation  medical  advice  contained in  100  medical  reports.  They  detected  that
most of the main diagnoses were smoking related diseases. From all reports, only 48% of
patients had history related to tobacco, 14 were smokers and 11 had in the report a writ‐
ten advice to quit smoking. Only 36.7% of smokers received smoking advice. Of the pa‐
tients who had no history, 16 were smokers and had not received advice. In addition, the
first hospital  admissions were 5.9% more likely to count with clinical history than read‐
missions  (77.8%  in  first  admission  compared  to  35.6%  in  readmissions).  An  interesting
finding  was  that  physicians  who  smoked  where  less  likely  record  the  smoking  history
than non-smoking physicians. The authors conclude that the interview related to tobacco
and smoking advice should be improved.
Sundblad, Larsson and Nathell [39] designed a smoking cessation program in which patients
were hospitalized for 11 days to develop their motivation to quit smoking through informa‐
tion, exercise the option to make a nicotine replace therapy, learning coping strategies and per‐
sonal support. The results on smoking were evaluated after 1 and 3 years. The abstinence was
compared in the patients with COPD who participated in the smoking cessation program (N =
247) and the ones receiving usual care (N = 231). Abstinence rates obtained in smoking cessa‐
tion group at one year were 52% and 38% at follow-up to three years.
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PSYCHOLOGICAL INTERVENTIONS
Author Objetive Patients Interventions Results Validation
Hilberink et
al. (2005)
To compare smoke cessation
rates depending on the type
of intervention.
392 smokers with
COPD
IG: brief intervention (counsel+ self-
help material)
CG: usual care (counsel)
Attempts to stop the smoking at
6 months:
IG: 44.9% vs. CG: 36.5%.
Abstinence at 6 months:
IG: 16.0% vs. CG: 8.8%.
Self-reports
Wilson et al.
(2006)
Evaluate the effectiveness of
interventions for smoking
cessation based on brief
counsel alone or with
support from nurses
(individual or group).
91 smokers with
COPD
IG 1=27
IG 2= 29
IG 3= 35
IG 1: individual support (briefings, self-
help materials and telephone support 5
weeks).
IG 2: group support by stage of change
(group information sessions + 5 follow-
up sessions after discharge).
IG 3: usual care (brief counsel).
Abstinence at 12 months:
IG 2: 10% vs CG: 6%.
There were no significant
differences between groups (p =
0.7).
Self-reports
Carbon
monoxide in
expired air
Cotinine in
saliva
PHARMACOLOGICAL TREATMENT COMBINED WITH A PSYCHOLOGICAL INTERVENTION FOR SMOKING CESSATION
Author Objetive Patients Interventions Results Validation
Tonnesen,
Mikkelsen &
Bremann
(2006)
To identify predictors of
abstinence
370 patients with
COPD who smoke
on average 19.6
cigarettes per day
IG1: sublingual tablet + low behavioral
support
IG2: sublingual tablet + high behavioral
support
CG1: sublingual tablet + placebo with
low behavioral support
CG2: placebo sublingual tablet + high
behavioral support
Prolonged abstinence
IG1: 14% vs.IG2: 14%
CG1: 5% vs.CG2: 6%
12 months point prevalence
IG1: 17% vs.IG2: 18%
CG1: 6% vs.CG2: 13%
Self-reports
Carbon
monoxide in
expired air
Christenhusz
, Pieterse,
Seydel & van
der Palen
(2007)
To evaluate the efficacy of
sublingual tablets or
placebo combined with two
levels of behavioral support
for smoking cessation in
COPD patients after
6 and 12 months.
225 patients with
moderate to severe
COPD
CG: moderately intensive intervention:
individual counseling + telephone
contacts Total time: 180 minutes.
IG: intensive intervention , group and
individual counseling and support
+phone calls + bupropion. Total time:
595 minutes.
Abstinence rates
CG:9%
IG:19%
Cotinine in
saliva Self-
reports
Tashkin et al.
(2001)
To investigate the effect of
bupropion promoting
abstinence from smoking in
patients with COPD
404 smokers with
mild or moderate
COPD who smoked
15 or more
cigarettes / day.
IG: bupropion (150 mg twice daily) +
counseling for smoking cessation
CG: placebo for 12 weeks + counsel
Abstinence at 6 months:
IG:28% vs. CG:16%.
Abstinence between weeks 4
and 12:
IG:18% vs. CG:10%.
Abstinence between weeks 4
and 26:
IG:16% vs. CG:9%.
Self-reports
Carbon
monoxide in
expired air
Wagena et
al.(2005)
Explore the efficacy of
bupropion and nortriptyline
in smokers with COPD risk
compared with smokers
with COPD.
255 adults at risk
for COPD or with
COPD
IG1:bupropion (15 mg twice daily)
IG2: nortriptyline (75 mg once/day X
12 weeks)
CG: bupropion placebo
Prolonged Abstinence 26 weeks:
IG1:27.9% vs. IG2:25% vs.
CG:14.6 %(p=0.03)
Self-reports
Carbon
monoxide in
expired air
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van Schayck
et al.(2009)
Netherlands
To evaluate the efficacy of
bupropion and nortriptyline
compared with placebo in
smokers with COPD risk
255 COPD risk IG 1: Bupropion-12 weeks
IG 2: nortriptyline -12 weeks
CG: Placebo 12 weeks
Prolonged Abstinence:
IG1:20.9%, IG2: 20%, G.C:13.5%
Significant differences between
bupropion and placebo [RR=1.6,
95% IC=0.8-3.0]
Cotinine in
urine
Self-reports
Tashkin et al.
(2011)
To evaluate the efficacy of
varenicline in patients with
COPD
504 patients with
mild and moderate
COPD
IG: Varenicline + educational booklet
on smoking cessation information and
brief sessions (10 minutes) telephone
counseling
CG: placebo + educational booklet on
smoking cessation information and
brief sessions (10 minutes) telephone
counseling
Continuous abstinence
IG:42.3%
CG:8.8%
p<.0001
Self-reports
Carbon
monoxide in
expired air
INTERVENTIONS FOR SMOKING CESSATION IN PATIENTS HOSPITALIZED FOR COPD
Author Objetive Patients Interventions Results Validation
Sundblad,
Larsson y
Nathell
(2008)
To evaluate a smoking
cessation program
478 COPD patients IG: hospitalization for 11 days were
used to develop the motivation to quit
smoking through information, exercise
the option to take a nicotine
replacement therapy, learning coping
strategies and given personal support
CG: usual care
Abstinence rates at 12 months
IG: 52% vs. CG: 7%
Abstinence rates at 3 years
IG: 38% vs. CG: 10%
Self-reports
Carbon
monoxide in
expired air
Borglykke,
Pisinger,
Jørgensen &
Ibsen (2008)
To evaluate the effect of a
smoking cessation group in
hospitalized patients with
COPD
223 hospitalized
patients with COPD
IG: Participants attended group
intervention sessions (two hours
weekly for five weeks) NRT was used
when necessary
CG: usual care
Abstinence rates at 12 months
IG:30%
CG:13%
Self-reports
Carbon
monoxide in
expired air
IG: Intervention Group; CG: Control Group; NRT: Nicotine Replace Therapy
Table 1. Interventions for smoking cessation in patients with chronic obstructive pulmonary disease (COPD).
Also, Borglykke, Pisinger, Jorgensen and Ibsen [40] evaluated the effect of a smoking cessa‐
tion group in hospitalized patients with COPD. Patients were assigned to a control group (n
= 102) or an intervention group (n = 121). In the first two sessions of the intervention, the
group received information on smoking cessation and had to set a date to start the with‐
drawal that was supported NRT when necessary. At 1 year follow-up 36 (30%) patients in
the intervention group remained abstinent compared with 13 (13%) patients in the control
group [odds ratio (95% confidence interval): 2.83 (1.40 -5.74). A significant difference was
observed between the intervention group and control group with respect to the self report‐
ing of the phlegm production however no significant improvement was observed in terms
of survival benefit at 3 years follow up period (intervention group 86% vs. control group
85%).Therefore, the authors conclude that this study showed that a group intervention for
chronic patients made it possible to get high withdrawal rates. Furthermore, this interven‐
tion showed positive impact in hospitalization in survival and reducing phlegm.
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9. Training of professionals who carry out interventions for smoking
cessation
Ballbé et al. [41] assessed if the lack of promotion on the cessation of smoking in hospitals is
due to deficits in professional training. In this study, knowledge, attitudes and action re‐
garding the smoking behavior of 66 health professionals before and after training on brief
intervention was evaluated. The performance of these professionals with 170 patients was
compared before and another 170 training (patient’s report). It was found was that the inter‐
vention training for smoking cessation increases knowledge of psychological skills by 23.3%
and 27.1% of pharmacological resources. However no changes were observed with respect
to the question of whether to smoke (30.8% before vs. 38.2% after training), to records the
smoking status of patient medical history (73.4% vs. 65.9%), whether the patient want to quit
(25% vs. 12.5%) or with respect to anti-smoking advice (21.9 % vs. 20.8%). This study shows
that health care activity in hospitals tends to focus on treating specific diseases for which pa‐
tients attend, and leave behind preventive interventions, even when the professionals have
the training.
In a same line, Efraimsson, Fossum, Ehrenberg, Larson and Klang [42] tried to assess wheth‐
er with a four-day training in motivational interviewing, a group of nurses will assume the
communication style of motivational interventions (MI) for smoking cessation in primary
care conducted with smokers with COPD. The nurses in their practice did not take the con‐
tents of the training they have received, which indicates that a course in motivational inter‐
viewing a few days was insufficient. It is concluded that training in communication
methods should be integrated into the nursing curriculum, since the management of MI is a
complex skill that requires a great workout.
In addition, sometimes personnel not sufficiently trained carry out the interventions. For ex‐
ample, Wilson et al. [27] obtained no differences between the interventions applied. The au‐
thors attribute the lack of success to patients and we must not forget that nurses who had
received only 6 hours of training applied such interventions. It would be interesting to eval‐
uate the results when intervention is performed by a psychologists with sufficient training
in smoking cessation.
10. Discussion
The aim of this study was to conduct a review of the effectiveness of  the treatments to
quit  smoking in patients with COPD, identifying the main difficulties to maintain absti‐
nence and to propose strategies to eliminate such obstacles. As a result of the revision, we
can say that although it is known how smoking affects COPD, the research attempting to
demonstrate the benefits of quitting smoking on health in smokers diagnosed with COPD
is insufficient. In addition, smoking history and the advice or counsel is not always a pri‐
ority in hospitals. A large percentage of health professionals do not ask to patients if they
smoke, therefore do not advise to quit, even though many of them have received formal
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training [41, 43-44]. Moreover, according to a survey, the majorities of patients are not of‐
fered help to quit smoking or are advised to make a follow-up with the physician or con‐
tact with a trained professional [43].
In addition, in the available reports, the interventions are very diverse both in relation to
their content and in relation to their intensity. There are also differences in the professionals
that conduct the interventions: physicians, nurses, psychologists, counselors or any other
health personnel; this makes very difficult to compare results of different interventions. An
important aspect to consider when analyzing the data obtained in present review is the dif‐
ference in health staff that carried out the smoking cessation interventions, since their level
of training was not considered; therefore, this could influence the results and the effective‐
ness of interventions. In some studies, nurses with little training to perform this task carried
out the interventions [27]. It would be interesting to compare the results obtained in inter‐
vention carried by different professionals with no specialized training with those obtained
by professionals who specializes in treating addictive behaviors.
In the studies reviewed, depending on the research involved, in some cases to calculate rates
of abstinence only self-reports were used [e.g. 25], while in others to corroborate self-report‐
ed abstinence different biochemical test were used. This is another important aspect to con‐
sider when analyze and interpreting present findings.
Another problem that limits replication is that many studies do not describe the procedure
followed in the psychological interventions, which could be central in the analysis of the re‐
sults. That is, in most reports only the use of behavioral cognitive interventions is reported,
but the techniques are not explained; therefore it is indispensable to specify and describe all
the techniques used for patients who want to quit smoking and COPD.
A different area identified is the lack of assessment of psychological factors associated with
relapse in the evaluation of different treatments, only side effects are evaluated with respect
to the use of drug treatments and only evaluates both the level of depression with the "Beck
Depression Inventory" and the level of motivation. Some reports suggest that depression
and anxiety are present in patients with COPD, but do not mention if it is consequence of
the disease or for quitting. It is known that lack of social support, depression, anxiety, anxi‐
ety sensitivity, negative affect, and deficiency of coping skills are factors associated with the
ineffectiveness of interventions in smokers without the diagnosis of a disease, but little is
known about the factors associated with relapse in the context of smoking cessation inter‐
ventions in patients with COPD.
On the other hand, in terms of difficulties for smoking cessation in patients with COPD the
review allowed to identify some factors:
• Many patients with COPD continue to smoke after diagnosis and those who manage to
quit smoking have a high rate of relapse, for that reason many patients do not try quit
again because their expectative is low.
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• In general, smokers with COPD have characteristics that make difficult to quit, for exam‐
ple the level of dependency is severe, the number of cigarettes is high [45]; they are older
and therefore have smoked for many years resulting in high dependency [46-47].
• A main barrier to quit smoking is the motivation. For example, in a study it was shown
that patients with COPD stop smoking according the motivational state (precontempla‐
tion, contemplation, preparation, action), smokers in precontemplation associated signifi‐
cantly fewer advantages to quit smoking compared with smokers in contemplation or
preparation stages. Smokers in preparation had significantly higher self-efficacy expecta‐
tions about quitting than other smokers. Patients in preparation for quitting complained
more about the symptoms associated with COPD. Smokers in contemplation and prepa‐
ration to quit developed more plans to try to switch to action to stop smoking [48]. At this
point, it is proposed to design an intervention for smokers with COPD motivated to quit
and other unmotivated.
• The comorbidity with anxiety and depression is very high, particularly in women [49-50].
This difficulties to achieve the abstinence and justifies the use of psychological treatments
to improve outcomes of smoking cessation treatments.
• Another factor that makes difficult to stop smoking is weight gain, particularly in women
[45]. When patients stop smoking and gain weight, symptoms related with COPD are ex‐
acerbated and causes relapses.
• Social support between the moments the patients are diagnosed COPD and when decide
to quit, is other factor. Some authors suggest that social support should be from a family
member or someone close to the patient, instead of for example, another patient with
COPD [46,51].
11. Conclusions
From present review about the interventions for smoking cessation and the identification of
barriers to achieve and maintain abstinence, we suggest the inclusion of different techniques
to overcome these barriers, since providing information about harm caused by smoking is
not enough. It is imperative that patients with COPD to realize how smoking is decreasing
their quality of life and deteriorating their health.
The motivational interviewing techniques [52-53] could be an effective method to support
smoke cessation [42], but require significant training [54]. It is suggested the inclusion of
motivational interviewing in the treatment for smoking cessation in smokers with COPD
and personalized feedback with the use of measures of spirometry, Fletcher curve and to ex‐
ploit the adverse events related to COPD to promote the decision of quitting [48]. En el pa‐
tient with COPD the motivation for quitting increases if patients perceive that the
respiratory symptoms are due to use of tobacco [55].
Problem-Solving Therapy helps patients to effectively deal with diverse problems from dif‐
ferent learning strategies [56]. The objective of this therapy is to clearly define the problem,
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propose alternatives to solve the problem make decisions and implement solutions to assess
the effectiveness of the alternative. For patients with COPD the strategies can be applied not
only to the problems associated with quitting smoking, but also to emerging situations by
the presence of the disease, such as social, physical and economic problems.
Functional analysis of problem behavior consists in the identification of the context of occur‐
rence of the inadequate behavior and the consequences that maintain it. In treatments for
smoking cessation implies the clear identification of the situation that triggers the consump‐
tion of cigarettes, and the positive and negative consequences of consumption, in order to
plan and apply strategies that lead to abstinence from cigarettes [57].
Self-monitoring is a technique in which the patient is asked to record the duration, frequen‐
cy and severity of the problem behavior. In the context of smoking cessation treatment, par‐
ticularly in patients with COPD, it may ask the patient to record each cigarette consumed,
the place of consumption, how it feels when smoke each cigarette, and to register the pres‐
ence and severity of respiratory symptoms.
The proposal of a individualized plan for quitting would consist of two phases, one evalua‐
tion phase and the intervention phase that will include the techniques mentioned. In the
evaluation phase, the goal would be to get specific information of psychological factors re‐
lated with the consumption of cigarettes by the patient with COPD, to consider the individ‐
ualized treatment.
Initially, it would be necessary to identify the stage of readiness to change [26], the pattern
of consumption of cigarettes (daily average consumption per day, monthly consumption),
identified the factors causing the consumption (moods, places, people or their combination)
and the level of anxiety, depression, negative affection, social support, the level of depend‐
ency and the coping strategies of the patient.
From the results of the evaluation would be conducted a personalized feedback and deci‐
sional balance would be applied using the techniques of motivational interviewing (empa‐
thy, reflective listening, cognitive dissonance, without confrontation).
Based on the decisional balance the person must choose one of two strategies for reaching
abstinence: 1) gradual reduction of the nicotine and tar consisting in the decline of 30 % of
the initial consumption pattern every week until it reaches 0 %, or 2) abstinence.
To initiate strategies to abstinence from cigarettes consumption, start a record of a functional
analysis of the behavior of smoking. This analysis include the negative effects of abstinence
(nervousness, irritability, anxiety, depression, hunger, trouble sleeping) and the positive ef‐
fects of abstinence, i.e. the registration of the reduction of the problems of the COPD from
the change in the pattern of consumption (phlegm, breathing problems, cough).
Also, teach patients coping strategies for anxiety, depression, negative affect, and problem
solving strategies to apply during periods in which the patient is still in situations or in the
presence of factors (moods or people) that cause the consumption of cigarettes.
To summarize, the revisions point out that in COPD the smoking cessation programs should
be intense, sustained over time and adapted to each patient individually. It also emphasizes
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the need of combining pharmacological and psychological treatments, particularly behavio‐
ral focused to the relapse prevention and stress management [58,59]. What is clear is that
smoking intervention should be considered as a substantial part of the treatment of COPD.
The psychological techniques mentioned previously, could help to eliminate barriers and
provide personalized feedback to increase abstinence rates in patients with COPD.
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